Northern Ireland-based biotech startup Dia Beta Labs has secured €1.4 million in funding. This investment supports its development of next-generation therapies for obesity and Type 2 diabetes. Undisclosed investors participated in the round.
Advancing Beta-Cell Regeneration
Dia Beta Labs, founded in 2022, creates specially designed human-based peptides. These peptides protect and repair the pancreas's insulin-producing beta-cells. This approach aims to slow or reverse disease progression, offering a sustainable solution for diabetes cell therapies.
The company's technology differs from current drugs, which primarily lower blood sugar or reduce appetite. Dia Beta Labs focuses on cell recovery and regeneration. This could manage symptoms and potentially reverse the disease, unlike traditional treatments from companies like Novo Nordisk.
The €1.4 million funding will advance research in metabolic diseases. Dia Beta Labs contributes to the global effort to manage the diabetes and obesity crisis, a key area in biotech innovation. Their work complements other advancements in precision medicine.